登录 注册 会员服务 联系我们

Heterogeneity of [68Ga]Ga-PSMA-11 PET/CT in metastatic castration-resistant prostate cancer: genomic characteristics and association with abiraterone response

  • Published:2023-01-31 Issue:6 Volume:50 Page:1822-1832
  • ISSN:1619-7070
  • Container-title:European Journal of Nuclear Medicine and Molecular Imaging
  • language:en
  • Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Pan JianORCID,Zhao Jinou,Ni Xudong,Zhu Bin,Hu Xiaoxin,Wang Qifeng,Wei Yu,Zhang Tingwei,Gan Hualei,Wang Beihe,Wu Junlong,Song Shaoli,Liu Chang,Ye Dingwei,Zhu Yao

Funder

National Natural Science Foundation of China

Beijing Xisike Clinical Oncology Research Foundation

Shanghai Medical Innovation Research Special Project

Shanghai Shenkang Research Physician Innovation and Transformation Ability Training Project

Clinical Research Plan of SHDC

Shanghai Sailing Program

Shanghai Anti-Cancer Association Eyas Project

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Reference37 articles.

1. Kyriakopoulos CE, Heath EI, Ferrari A, Sperger JM, Singh A, Perlman SB, et al. Exploring spatial-temporal changes in (18)F-sodium fluoride PET/CT and circulating tumor cells in metastatic castration-resistant prostate cancer treated with enzalutamide. J Clin Oncol. 2020;38:3662–71. https://doi.org/10.1200/JCO.20.00348.

2. Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, et al. Positron emission tomography/computed tomography-based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration-resistant prostate cancer. JAMA Oncol. 2018;4:217–24. https://doi.org/10.1001/jamaoncol.2017.3588.

3. Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195:1436–43. https://doi.org/10.1016/j.juro.2015.12.025.

4. Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, et al. NCCN guidelines insights: prostate cancer, version 1.2021. J Natl Compr Canc Netw. 2021; 19;134–143. https://doi.org/10.6004/jnccn.2021.0008.

5. Fanti S, Briganti A, Emmett L, Fizazi K, Gillessen S, Goffin K, et al. EAU-EANM consensus statements on the role of prostate-specific membrane antigen positron emission tomography/computed tomography in patients with prostate cancer and with respect to [(177)Lu]Lu-PSMA radioligand therapy. Eur Urol Oncol. 2022;5:530–6. https://doi.org/10.1016/j.euo.2022.05.003.
同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3